Odyssean LLC Buys Shares of 95,069 Celldex Therapeutics, Inc. $CLDX

Odyssean LLC purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 95,069 shares of the biopharmaceutical company’s stock, valued at approximately $3,538,000. Celldex Therapeutics accounts for 0.6% of Odyssean LLC’s holdings, making the stock its 6th largest position.

A number of other large investors also recently modified their holdings of the business. Nykredit A S bought a new stake in shares of Celldex Therapeutics in the second quarter valued at approximately $67,000. Montanova Capital LLC bought a new position in Celldex Therapeutics during the second quarter worth $4,513,000. Wellington Management Group LLP raised its stake in Celldex Therapeutics by 11.5% during the 2nd quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company’s stock valued at $355,120,000 after purchasing an additional 983,195 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Celldex Therapeutics in the 2nd quarter valued at $8,342,000. Finally, Handelsbanken Fonder AB boosted its holdings in Celldex Therapeutics by 5.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock valued at $1,012,000 after purchasing an additional 1,300 shares during the period.

Analyst Ratings Changes

CLDX has been the topic of several research analyst reports. Barclays raised their price target on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Guggenheim increased their target price on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Canaccord Genuity Group decreased their target price on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. Wells Fargo & Company boosted their price target on Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Morgan Stanley boosted their price target on Celldex Therapeutics from $40.00 to $46.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.08.

Celldex Therapeutics Stock Performance

CLDX opened at $39.68 on Friday. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of -9.12 and a beta of 0.84. Celldex Therapeutics, Inc. has a twelve month low of $22.10 and a twelve month high of $45.14. The firm’s 50-day simple moving average is $39.07 and its 200-day simple moving average is $33.80.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.73 million. As a group, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -4.13 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.